• slidebg1

    Collaborate

    CRISPR is an early-stage company
    created to translate breakthrough
    gene-editing technology into transformative
    medicines for serious human diseases.
    Abingworth is helping CRISPR to select
    its first therapeutic indications
    and build its team.

  • slidebg1

    Innovate

    Nasdaq-listed Paratek is developing novel
    antibiotics to tackle community-acquired
    infections. Abingworth helped recruit the
    team and co-led the investment.

  • slidebg1

    Create

    GammaDelta is exploiting the unique
    properties of tissue resident γδ T cells for
    effective immunotherapy. Abingworth has
    supported and incubated the young UK
    company since its inception.

  • slidebg1

    Collaborate

    Avillion is a clinical co-development
    company providing funding and
    operational expertise to accelerate
    the development of late stage
    therapeutics. Abingworth created and
    incubated the UK-based company.

  • slidebg1

    Innovate

    Abingworth is working with eFFECTOR to
    develop a novel class of small molecule drugs
    that selectively regulate translational
    control of gene expression. The clinical stage
    company has an initial emphasis on cancer,
    including immuno-oncology.

  • slidebg1

    Create

    SutroVax is developing a potential best-in-class
    conjugate vaccine to prevent invasive
    pneumococcal disease, which can cause
    pneumonia, meningitis and blood stream
    infections. Abingworth led the series A financing
    and helped with the company’s business
    development and expansion plans.

Latest News
27 Mar 2017
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne  Read More
22 Mar 2017
Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554  Read More
21 Mar 2017
SutroVax Announces Closing of $64M via Series B Financing   Read More
See all Films
 

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Collaborate
CRISPR is an early-stage company created to translate breakthrough gene-editing technology into transformative medicines for serious human diseases. Abingworth is helping CRISPR to select its first therapeutic indications and build its team.
Innovate
Nasdaq-listed Paratek is developing novel antibiotics to tackle community-acquired infections. Abingworth helped recruit the team and led the investment.
Create
GammaDelta is exploiting the unique 
properties of tissue resident γδ T cells for 
effective immunotherapy. Abingworth has 
supported and incubated the young UK 
company since its inception.
Collaborate
Avillion is a clinical co-development company providing funding and operational expertise to accelerate the development of late stage therapeutics. Abingworth created and incubated the UK-based company.
Innovate
Abingworth is working with eFFECTOR to develop a novel class of small molecule drugs that selectively regulate translational control of gene expression. The clinical stage company has an initial emphasis on cancer, including immuno-oncology.
Create
SutroVax is developing a potential best-in-class conjugate vaccine to prevent invasive pneumococcal disease, which can cause pneumonia, meningitis and blood stream infections. Abingworth led the series A financing and helped with the company’s business development and expansion plans
 
Latest News
27 Mar 2017
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne  Read More
22 Mar 2017
Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554  Read More
21 Mar 2017
SutroVax Announces Closing of $64M via Series B Financing   Read More
See all Films
Copyright Abingworth 2017